Migraine Prevention Breakthrough: CGRP Antibody Drugs Halve Symptoms in 50% of Patients, Keio Study Finds
A Keio University study reveals CGRP antibody drugs reduced migraine frequency by half in about 50% of patients, with over 90% satisfaction. Explore Japan's latest migraine prevention treatments—from monthly injections to upcoming oral medications and neuromodulation—and how they're transforming life for migraine sufferers.